13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
89,760 |
27.06.24 17:06:31 |
-1,120 |
-1,23% |
89,730 |
89,910 |
90,210 |
90,880 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
993,000 |
27.06.24 08:12:54 |
-13,500 |
-1,34% |
979,600 |
986,200 |
993,000 |
1.006,500 |